Invivyd Appoints Marc Elia as New CEO to Lead Viral Infectious Disease Protection Efforts

NEW HAVEN, Conn., Invivyd, a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, announced on September 1, 2026, that it has appointed Marc Elia, the current Chairman of the Invivyd Board of Directors, as its new Chief Executive Officer (CEO). Elia will also continue to serve as Chairman of the Board, effective immediately.

Ajay Royan, Lead Independent Director of Invivyd, emphasized Elia's critical role in the company's future, stating, "Invivyd is transforming the landscape of viral infectious disease protection, and Marc Elia is the visionary leader who can help us achieve that goal. Marc's extensive contributions to Invivyd since joining the Board and becoming Chairman have been instrumental, and I am confident that he will lead the company to new heights."

Elia expressed his enthusiasm for the role, saying, "Invivyd and its antibody technologies have the potential to revolutionize how we prevent and treat viral infections, particularly COVID-19. Our goal is to provide reliable, targeted, and high-quality monoclonal antibody support that can protect Americans and the world from the ongoing threat of viral diseases. I am honored to lead Invivyd in this critical time."

In addition to Elia's appointment, Invivyd has added Ian Sheffield, a healthcare investor and medical technology executive, to its Board of Directors. Sheffield's extensive experience spans over two decades, with roles at firms such as Ashler Capital, Bridger Capital, Great Point Partners, and Versant Ventures.

Invivyd is currently in the final stages of conducting two key clinical trials: DECLARATION and LIBERTY. These studies are evaluating VYD2311, a novel monoclonal antibody (mAb) designed to address the urgent need for new prophylactic and therapeutic options for COVID-19. Top-line data from these trials are expected by the end of the third quarter of 2026, and the company plans to either unblind the DECLARATION study in its entirety or partially unblind it to facilitate a Biologics License Application (BLA) submission. The company believes that either approach can provide a near-term pathway to making VYD2311 available to millions of Americans.

VYD2311 is a cutting-edge mAb candidate that leverages Invivyd's proprietary integrated technology platform to generate antibodies optimized for neutralizing contemporary virus lineages. It is designed to offer more patient-friendly administration methods, such as intramuscular injection, compared to traditional administration routes.

The DECLARATION study, a Phase 3, randomized, triple-blind, placebo-controlled trial, aims to evaluate VYD2311's efficacy and safety in preventing symptomatic COVID-19 in a broad population, including adults and adolescents. The LIBERTY trial, a Phase 3, randomized, double-blind study, will assess the safety, serum virus neutralizing antibody responses, and pharmacokinetics of VYD2311 in combination with an mRNA COVID-19 vaccine.

Invivyd's commitment to developing innovative antibody technologies and addressing the public health challenges posed by viral infectious diseases continues to advance the company's mission. The company remains optimistic about the potential of VYD2311 to transform the landscape of viral disease prevention and treatment.